Secondary metabolites of *Schisandra chinensis* in homeostasis regulator adaptogen herbal formula for preventive oncology

Olga A. Bocharova¹, Ilia V. Kazeev¹, Valeriy E. Shevchenko¹, Nikita S. Ionov², Olga PSheichenko³, Evgeny V. Bocharov¹, Regina V. Karpova⁴, Valerian G. Kucheryanu⁵, Alexey A. Lagunin⁶, Dmitry A. Filimonov⁷, Vyacheslav B. Kosorukov⁴, Vladimir V. Poroikov⁴, Victor A. Tutelyan⁸, Natalya V. Pyatigorskaya⁹

¹The N.N. Blokhin National Medical Research Center of Oncology, 24 Kashyrskoe shosse, Moscow, 115478, Russia; ²All-Russian Research Institute of Medical and Aromatic plants, 7/1 Greena Str., Moscow, 117216, Russia; ³Institute of general pathology and pathophysiology, 8 Baltiyskaya Str. Moscow, 125315, Russia ⁴Institute of Biomedical Chemistry, 10/8 Pogodinskaya Str., Moscow, 19121, Russia ⁵Federal Research Center for Nutrition, Biotechnology and Food Safety, 2/14 Ustyinsky proezd, Moscow, 109240, Russia; ⁶Sechenov First Moscow State Medical University (Sechenov University), 8, Trubetskaya Str., Moscow, 119991, Russia

*Corresponding author:  +7 925-991-73-80  ilya_delta@mail.ru

Abstract

The original herbal formula of homeostasis regulator Multi-phytodadaptogen (MPhA) for preventive oncology developed by the N.N. Blokhin Center of Oncology containing phyto-components from *Schizandra chinensis* has been investigated in vitro, in vivo and in clinical studies. The MPhA multi-target effects are achieved by optimizing the functioning of the nervous, immune and endocrine defense systems that regulate homeostasis under stress. Everything that has been previously studied for MPhA can be considered as preclinical testing, including clinical research, which can be regarded as the pilot studies. This was allowed because MPhA in Russia is registered as a parapharmaceutical agent and therefore standardized according to established requirements. However, due to the high efficiency of MPhA, a detailed study of the chemical composition and standardization of it is required, including the composition of *Schisandra chinensis* Baill. (Schisandraceae) active components, which turned out to be translocated into MPhA as a result of the extraction technology developed. So, for MPhA identification and standardization we detected the secondary metabolites in the herbal formula MPhA as well as in fruits extract of *Schisandra chinensis* using high-performance liquid chromatography in combination with mass spectrometry. Chromatography was performed on an ACQUITY UPLC BEH C18 column in a gradient mode. A TSQ Vantage triple quadrupole mass spectrometer with electrospray ionization was used. Lignans Schizandrin and Schizantherin A were identified in the MPhA as well as in *Schisandra chinensis* fruits extract obtained by the technology developed. The determined secondary metabolites can be used for standardization and quality testing of the herbal formula MPhA. In addition, we performed in silico analyzes of Schizandrin and Schizantherin A biological activity spectra using computer program PASS (Prediction of Activity Spectra for Substances). Schizandrin and Schizantherin A activities, according the scientific literature and in silico analysis, correspond to the properties studied for MPhA which therefore fits into the concept of a drug – homeostasis regulator adaptogen for preventive oncology.

Keywords

Herbal formula MPhA; Schisandra chinensis; Schizandrin and Schizantherin A, adaptogen; Homeostasis regulator, Preventive oncology; Standardization; HPLC-MS/MS spectroscopy; PASS; PharmaExpert; in silico analysis

Imprint


1. Introduction

Adaptogens comprise a category of herbal medicinal and nutritional products promoting adaptability, resilience and survival of living organisms in stress. The multi-target effects of adaptogens are achieved by optimizing the functioning of the nervous, immune...
and endocrine defense systems – regulatory axes of homeostasis under stress. These effects include triggering intracellular and extracellular adaptive signaling pathways that promote cell survival and body resistance to stress; regulation of metabolism and homeostasis by affecting the expression of stress hormones (cortisol, catecholamines, corticotropin- and gonadotropin-releasing hormones, urocortin, melatonin, heat shock proteins Hsp70, neuroptide Y etc.) and their receptors. Adaptogens are used as official medicines in the USSR/Russia, as well as in traditional Chinese and Korean medicines, Ayurveda, Campo, and other traditional medical systems [1-11].

This provides a basis for evaluating the use of adaptogens in the treatment of stress-related and aging-related diseases, including cancer. Adaptogens must be innocuous and cause minimal disorder in the physiological functions of an organism and have nonspecific actions, that is, increase resistance to adverse influences of a wide range of factors with physical, chemical, and biological properties. In addition, they typically possess normalizing actions irrespective of the foregoing pathologic changes direction [12-21].

Classical phytoadaptogens include Panax ginseng, Rhodiola rosea, Aralia mandshurica, Eleutherococcus senticosus, Oplopanax elatus, Schizandra chinensis, etc. The biologically active substances (BAS) of many phytoadaptogens (from ginseng, rhodiola, eleutherosoccus, aralia etc.) have been identified, extracted and purified. It was shown that in purified forms some active substances of phytoadaptogens exhibit pronounced toxicity in vitro and in vivo models [1, 22]. Besides that, the use of individual phytoadaptogen extract is often limited by the drug resistance that is developed over the time of administration [9]. In this regard, studies of phytotcomplexes based on the principle of BAS rational combination and providing unique synergistic effects, which cannot be obtained using a separate phytoadaptogen, are scientifically justified and relevant. Moreover, the use of several adaptogens in a particular pharmaceutical composition allows affecting the body without causing addiction. At the same time, both the standardization and the justification problem of the multicomponent phytoadaptogens pharmacological activity taking into account their chemical composition are relevant [16, 18, 23, 24].

The original herbal formula Multiphytoadaptogen (MPhA) for preventive oncology was developed in the N.N. Blokhin National Medical Research Center of Oncology [22, 29]. MPhA contains components of 40 official plants extracts, including adaptogens Panax ginseng, Aralia mandshurica, Eleutherococcus senticosus, Rhodiola rosea, Oplopanax elatus, Schizandra chinensis. MPhA has been shown to be effective in preventive oncology. As it is known, preventive oncology includes primary (prophylaxis of the occurrence, or chemoprophylaxis), secondary (prophylaxis of relapses and metastases) and tertiary (prophylaxis of chemo-radiation therapy side effects) prophylaxis of cancer diseases [22]. No doubt, antitumor and protective effects are the main properties that medications for preventive oncology should exhibit. Experimental and clinical studies have revealed antimutagenic (which is important for primary cancer prevention), antitumor (essential for secondary prevention), radioprotective, hormone-modulating, antioxidant, neuroprotective, immunomodulatory, including adhesive and interferon-inducing effects of MPhA (which is important for tertiary cancer prevention) [22, 25-29]. Everything that has been previously studied for MPhA (in vitro, in vivo and in clinics) can be considered as preclinical testing, including clinical research, which can be regarded as the pilot studies. It was allowed because MPhA in Russia is registered as a parapharmaceutical agent and therefore standardized according to established requirements. However, due to the high efficiency of MPhA, a detailed study of the chemical composition and standardization of it is required.

The effectiveness of the MPhA is due to the complex of BAS included in its composition. To assess the possibilities of quality control and standardization of the MPhA, studies are being performed to determine the BAS of its composition. Thus, using the reverse-phase high-performance liquid chromatography with a UV detector and gas chromatography-mass spectrometry, polyphenolic compounds, essential oils, amino acids were detected in MPhA [30-32]. Among the components of MPhA, the main BAS in Ginseng and Aralia – triterpene saponins (ginsenosides Rb1, Rb2, Rc, Rd, Rg1, Rg2, Re, Rf, Ro and aralosides A, B, C) were identified by high-performance liquid chromatography in combination with tandem mass spectrometry (HPLC–MS/MS) [33, 34]. Phenylethanol-glycoside (salidroside), phenylpropanoid glycosides (rosavin and rosarin), monoterpen glycoside (rosirdine) and flavonoid (rhodioline) were also identified as components of Rhodiola rosea BAS as well as phenol (eleutheroside B) and lignan (eleutheroside E) from
The compounds identical to ginsenosides Re and Rd with araloside C were identified in MPhA as components of Oplopanax elátus (triterpene glycosides) [37].

The next stage of the MPhA components analysis using HPLC-MS/MS is to determine Schisándra chinénsis Baill (Schisandraceae) fruits extract BAS which turned out to be translocated into MPhA as a result of the extraction technology developed. HPLC-MS/MS method is characterized by specificity and high accuracy, which makes it possible to determine substances in minimal quantities [33-37].

The term adaptogen was introduced in 1958 by the Soviet toxicologist N.V. Lazarev, who applied it to the synthetic stimulant dibazol (2-phenyl-imidazol) assuming that adaptogens increase the nonspecific resistance of organisms under conditions of stress resulting in increased endurance, stamina, and performance. This assumption was based on the results of intensive studies of Schisandra chinensis in the USSR during World War II, with the goal of finding an alternative to stimulants used by the German and U.K. army to increase the attention and endurance of pilots.

The aim was also to supply the Soviet Armed Forces and Military Industry (soldiers, pilots, sailors, and civilians engaged in the production of weapons and war materials) with easily available natural stimulants, presumably extracts from S. chinensis berry or seeds. The interest in S. chinensis arose from ethnopharmacological investigations by V.L. Komarov (1895) and V.K. Arsenyev (1903–1907) in far eastern Siberia and northern Manchuria. The berries and seeds were determined to have been used by Nanai hunters (natives of far eastern Siberia and Chinese Manchuria) as a tonic to reduce thirst, hunger, and exhaustion and to improve night-time vision [1]. The first studies on the stimulating and tonic effects on S. chinensis were published in World War II-era military journals. During the 1960s and 1970s, other Soviet scientists extended the research of adaptogens to “rejuvenating and invigorating” medicinal plants traditionally used in China, Korea, Japan, Siberia and the far east of the USSR for a variety of pathological conditions including diseases and their symptoms such as hypodynamia, asthenia, shortness of breath, insomnia, impotence, and diabetes etc[1].

Schisándra chinénsis Baill (Schisandraceae) is a perennial, woody, deciduous, climbing vine from the Schisandraceae family. Also, this plant has many folk names, such as “Chinese schizandra”, “Manchurian schizandra “ and “ts-wei-tzu”, which means “berry of five flavors” in Chinese. It grows mainly in China, Japan and Korea. In its wild form on the territory of Russia it is distributed in the Far East, in the Primorsky and Khabarovsk Territories, in the Amur Region and on Sakhalin. It mainly grows on drained, humus-rich soils. The plant is light-loving, so it does not tolerate strong shading [38]. The juice of Schisándra chinénsis fruits contains a large amount of sugars and organic acids (mainly citric, malic, tartaric). There is also a high content of vitamins – ascorbic acid, thiamine and riboflavin. Tocopherol, schizandrin, schizandrol etc. are noted in the seeds. The bark and other parts of the plant contain essential oil. It is highly valued in perfumery for its delicate spicy-lemon aroma. The composition of the essential oil includes sesquiterpene hydrocarbons, aldehydes and ketones. Fatty oil includes α-linoleic, β-linoleic, oleic and near marginal acids [39]. Tincture of Schisándra chinénsis seeds has hepatoprotector and antioxidant actions. It is used for asthenic syndrome, fatigue, in complex therapy with weakening of sexual function, convalescence after somatic and infectious diseases, to improve the body’s performance under increased mental stress [40]. In dermatology, infusions and tinctures of Schisándra chinénsis fruits as a tonic and adaptogen are used for infectious, allergic and viral skin diseases, psoriasis [41, 42].

The aim of our study was to identify biologically active substances of Schisandra chinensis in MPhA by HPLC-MS/MS and to evaluate the biological activity profiles of identified phytocomponents using in silico analysis.

2. Materials and Methods

2.1 Solutions

Samples of MPhA as well as Schisándra chinénsis extract were prepared using high-quality-certified raw materials. We studied samples of MPhA and Schisándra chinénsis extract obtained in the same way (same specific gravity of raw materials, temperature and time regime of extraction, composition of the extractant, etc.). MPhA and Schisándra chinénsis extract were analyzed using a TSQ Vantage triple quadrupole mass spectrometer (Thermo Scientific TSQ series) connected to an Accela HPLC chromatograph equipped with an ACQUITY UPLC BEH C18 column (1.7 μm, 2.1 × 100 mm, Waters).

Issue 27. May 2023 | Cardiometry | 65
The MPhA sample was mixed with methanol in a ratio of 1:2 and centrifuged for 5 min at 13000 rpm. The filler liquid was passed through a filter with a pore diameter of 0.22 microns and centrifuged at 13,000 rpm for 1 min. Aliquots (1 ml) of Schisandra extract were evaporated on a Concentrator 5301 rotary evaporator (Eppendorf, Germany) at 30 °C to dry. The residue was dissolved in 100 μl of methanol and centrifuged at 13,000 rpm for 1 min. The samples were analyzed using a triple quadrupole mass spectrometer TSQ Vantage (Thermo Scientific TSQ series) connected to the Accela HPLC chromatograph.

2.2 Chromatographic analysis

Chromatographic analysis conditions: ACQUITY UPLC BEH C18 column (1.7 microns, 2.1 × 100 mm, Waters); mobile phase composition: phase A – 100% water and 0.1% formic acid (FA); phase B – 95% acetonitrile, 5% water and 0.1% FA. For the analysis of extracts, the gradient of the mobile phase supply (in% of phase B) was used: 0-68 min (0-60%), 68-70 min (60-100%), 70-75 min (100%), 75-80 min (0%). Samples in the volume of 5 μl were injected into the injector loop with a volume of 25 μl (mobile phase – 20 μl), the flow rate of 450 μl/min.

Ionization was carried out using an electrospray. Ionization conditions: negative polarity, spray capillary voltage 4 kV, gas (creating spray) – 60 psi, flowing gas – 15 rel. units, capillary temperature – 270 °C. The spectra in the full ion scanning mode and in the selected ion monitoring mode (SIM) were taken in the range of 150-1500 Da, the scanning time is 0.1 s.

Mass spectra were obtained by direct injection of a sample through a syringe at a rate of 5 μl/min; the gas pressure in the collision chamber was 0.9 torr. The voltage in the collision chamber was selected for each connection separately.

2.3 The calculation of the probable spectra of the biological activity

The biological activity spectra of Schisandra chinensis secondary metabolites were calculated using the PASS 2022. PASS 2022 allows predicting 1957 biological activities with an average accuracy of 97%. The PASS algorithm is based on a naive Bayesian classifier and a representation of the structure of chemical compounds in the form of MNA descriptors. The result of prediction is a list of probable activities for each compound with the corresponding probability estimates Pa and Pi – probabilities of belonging to the classes of “actives” and “inactives”, respectively. All activities for which the calculated values of Pa exceed Pi are considered as probable. The analysis of the integral action and possible drug-drug interactions of chemical compounds established in Schisandra chinensis was performed using the computer program PharmaExpert [29, 43]. The efficiency of the approach using the PASS and PharmaExpert computer programs to analyze the possible biological activities of single phytocomponents and their complexes has been shown in numerous studies [44-50].

3. Results and discussion

To study the main BAS of Schisandra chinensis fruit extract that is part of the MPhA, a chromatogram of the extract was obtained taken in the full ion scanning mode. The chromatogram is shown in Figure 1.

Analysis of the literature data on the chemical composition of Schisandra chinensis fruits has revealed the most important biologically active compounds of this plant. They are Schizandrin A, B, C, Schizandrol A and B, etc. Table 1 shows the molecular weights (MW) and structural formulas of these substances.

Table 2 presents the results of tandem mass spectrometry analysis of Schisandra chinensis extract (Rt, m/z of pseudomolecular ion and its fragments), as well as the molecular weight of the compound. As follows from Table 2 Schizandrin corresponds to one of the peaks with m/z 430.82 with a retention time Rt = 10.5-11.0 min as well as Schizantherin A corresponds to one of the peaks with m/z 535.0 with retention time Rt = 23.0-23.2.

Thus, the main Schisandra chinensis BAS which primarily include Shizandrin and Schizantherin A, were identified in the extract of Schisandra chinensis. Knowing the retention times corresponding to them and the m/z values of the main molecular ion the MPhA chromatogram was analyzed with respect to the content of Schisandra chinensis BAS. Figure 2 shows the MPhA chromatogram in the full ion scanning mode.

The analysis of the MPhA chromatogram obtained under the same conditions as the chromatogram of Schisandra chinensis extract was carried out in the selected ion monitoring mode (SIM) corresponding to the main molecular ions of Schisandra chinensis (based on the data given in Table 2).
Figure 1. Chromatogram of Schisándra chinénsis extract in the full ion scanning mode.

Figure 2. Chromatogram of MPhA in the full ion scanning mode.
As a result of the analysis, the desired peaks were found on the MPhA chromatogram and, thereby, the presence of Schizandrine and Schisantherin A in the pharmaceutical composition was confirmed.

It should be emphasized that the identification of individual substances is important to justify the biological activity of a multicomponent medication.

Application of in silico methods makes it possible to obtain additional theoretical substantiation of the identified biological activities of Schisandra chinensis extract’s BAS. Since this extract is a part of MPhA herbal formula used in preventive oncology, the antitumor spectra of individual phytocomponents and their combinations were evaluated. With this purpose,

<table>
<thead>
<tr>
<th>Major compound</th>
<th>MW, g/mol</th>
<th>Structural formula</th>
<th>Major compound</th>
<th>MW, g/mol</th>
<th>Structural formula</th>
</tr>
</thead>
<tbody>
<tr>
<td>Schizandrin (Schizandrol A) C_{24}H_{30}O_{7}</td>
<td>432,5</td>
<td><img src="image" alt="Schizandrin (Schizandrol A) Structural formula" /></td>
<td>Schizandrin A (Deoxyschizandrin) C_{24}H_{32}O_{6}</td>
<td>416,5</td>
<td><img src="image" alt="Schizandrin A (Deoxyschizandrin) Structural formula" /></td>
</tr>
<tr>
<td>Schizandrin B C_{23}H_{29}O_{6}</td>
<td>400,5</td>
<td><img src="image" alt="Schizandrin B Structural formula" /></td>
<td>Schizandrol B (Gomisin A) C_{23}H_{28}O_{7}</td>
<td>416,5</td>
<td><img src="image" alt="Schizandrol B (Gomisin A) Structural formula" /></td>
</tr>
<tr>
<td>Schizandrin C C_{24}H_{30}O_{6}</td>
<td>384,4</td>
<td><img src="image" alt="Schizandrin C Structural formula" /></td>
<td>Schisantherin A (Gomisin C) C_{30}H_{32}O_{9}</td>
<td>536,6</td>
<td><img src="image" alt="Schisantherin A (Gomisin C) Structural formula" /></td>
</tr>
<tr>
<td>Schisantherin B C_{28}H_{34}O_{9}</td>
<td>514,6</td>
<td><img src="image" alt="Schisantherin B Structural formula" /></td>
<td>Schisantherin C C_{28}H_{34}O_{9}</td>
<td>514,6</td>
<td><img src="image" alt="Schisantherin C Structural formula" /></td>
</tr>
</tbody>
</table>
we performed a prediction of 32 pharmacotherapeutic effects and mechanisms of antitumor action for each of the identified phytocomponents using the computer program PASS. The Pa-Pi values diagram of predicted antitumor effects for *Schisandra chinensis* secondary metabolites (Schisantherin A, Schizandrin) is shown in Figure 3.

As can be seen in Figure 3, at the threshold Pa>Pi for Schisantherin A 30 and for Schizandrin 32 antitumor effects are predicted 12 antitumor effects are predicted for compound Schisantherin A and 11 for compound Schizandrin at a Pa-Pi>0.5 threshold. Six most probable antitumor effects are presented in Table 3.

As shown in Table 3, Antineoplastic (lungs cancer) is predicted with the highest Pa-Pi value for Schisantherin A (Pa-Pi=0.92). Antineoplastic (lungs cancer) is predicted at Pa-Pi=0.81 for Schizandrin. Table 3 demonstrates that the first four antineoplastic effects are predicted for Schisantherin A with the highest Pa-Pi values. Antineoplastic (colorectal cancer) are predicted for both compounds with equal Pa-Pi values 0.77.

Using PharmaExpert we detected the most probable synergistic/additive mechanisms of the antineoplastic effects. 30 mechanisms of action associated with antitumor effects are predicted at the Pa>Pi threshold for Schisantherin A and Schizandrin. Six of them are predicted at a Pa-Pi>0.5 threshold. Data of the mechanisms of antitumor action predicted for the compounds under study at the Pa-Pi>0.5 threshold are presented in Table 4.

As can be seen from the data presented in Table 3, the three mechanisms of action predicted with the highest probability are Tubulin antagonist (Schisantherin A, Pa-Pi = 0.82), Antimitotic (Schisantherin A, Pa-Pi = 0.78), Apoptosis agonist (Schizandrin, Pa-Pi = 0.72).

An analysis of the literature devoted to the study of the identified compounds from *Schisandra chinensis* biological activity gave the following results. Schizandrin (Schizandrol A) and Schisantherin A (Gomisin C) exhibit antitumor, neuroprotective, immunomodulatory, antioxidant as well as with therapeutic potential to overcome multidrug resistance in cancer [51-61].

Table 2

The tandem mass spectrometry of *Schisandra chinensis* extract (Rt, m/z for the main molecular ion, as well as for fragments of the molecular ion) results, as well as the molecular weight according to the literature.

<table>
<thead>
<tr>
<th>Substance</th>
<th>MW</th>
<th>Rt, min</th>
<th>m/z</th>
</tr>
</thead>
<tbody>
<tr>
<td>Schizandrin C24H32O7</td>
<td>432.5</td>
<td>10.5-11.0</td>
<td>430.82 [M+H]- 394.3 384.8 368.5 354.4 340.6 325.5 310.5 296.5 288.69 178.5 151</td>
</tr>
<tr>
<td>Schisantherin A C30H32O9</td>
<td>536.6</td>
<td>23.0-23.2</td>
<td>535.0 [M+H]- 516.7 470.9 436.6 418.2 403.8 373.1 354.8 319.5 208.4 142.5 119.1 96.8</td>
</tr>
</tbody>
</table>
Figure 3. Diagram of positive Pa-Pi values for antitumor effects and compounds Schisantherin A, Schizandrin. Negative Pa-Pi values in this figure are not taken into account and are reduced to zero.

Table 3
Six most probable antitumor effects of Schisantherin A and Schizandrin predicted by PASS.

<table>
<thead>
<tr>
<th>Name</th>
<th>Antineoplastic effect</th>
<th>Pa-Pi</th>
</tr>
</thead>
<tbody>
<tr>
<td>Schisantherin A</td>
<td>Antineoplastic (lung cancer)</td>
<td>0.92</td>
</tr>
<tr>
<td>Schisantherin A</td>
<td>Antineoplastic (breast cancer)</td>
<td>0.89</td>
</tr>
<tr>
<td>Schisantherin A</td>
<td>Antineoplastic (carcinoma)</td>
<td>0.89</td>
</tr>
<tr>
<td>Schisantherin A</td>
<td>Antineoplastic (squamous cell carcinoma)</td>
<td>0.86</td>
</tr>
<tr>
<td>Schizandrin</td>
<td>Antineoplastic (lung cancer)</td>
<td>0.81</td>
</tr>
<tr>
<td>Schizandrin</td>
<td>Antineoplastic (breast cancer)</td>
<td>0.8</td>
</tr>
<tr>
<td>Schisantherin A</td>
<td>Antineoplastic (colorectal cancer)</td>
<td>0.77</td>
</tr>
<tr>
<td>Schizandrin</td>
<td>Antineoplastic (colorectal cancer)</td>
<td>0.77</td>
</tr>
</tbody>
</table>

Table 4
The most probable mechanisms of action associated with antineoplastic effects.

<table>
<thead>
<tr>
<th>Mechanism</th>
<th>Pharmacological Effect</th>
<th>Compound’s name</th>
<th>Pa-Pi</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tubulin antagonist</td>
<td>Antineoplastic (melanoma)</td>
<td>Schisantherin A</td>
<td>0.82</td>
</tr>
<tr>
<td></td>
<td>Prostate cancer treatment</td>
<td>Schizandrin</td>
<td>0.65</td>
</tr>
<tr>
<td></td>
<td>Antineoplastic (ovarian cancer)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Antineoplastic (gastric cancer)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Antineoplastic (breast cancer)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Antineoplastic (lung cancer)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Antineoplastic (bladder cancer)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Antineoplastic (cervical cancer)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Antineoplastic (colorectal cancer)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Antineoplastic (multiple myeloma)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Antineoplastic (pancreatic cancer)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Antineoplastic antibiotic</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Antineoplastic (renal cancer)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Antineoplastic antibiotic</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Antineoplastic (lymphoma)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
At the same time, it should be noted that the MPhA original herbal formula provides antiproliferative activity against ovarian and cervical adenocarcinomas as well as human hypernephroma in our in vitro studies. Experiments in vivo on high-cancer CBA mice-males have demonstrated potent MPhA effect against hepatocellular carcinoma. In vivo a 100% antimetastatic effect was found on Lewis lung carcinoma. Antitumor activity in stage four advanced gastric cancer has been shown in the clinics. Chemopreventive (oncophrophylaxis) effect was demonstrated in CBA mice as well as in the clinics for the treatment of precancerous oral leukoplakia. An evidential therapeutic effect of MPhA in relation to age-related pathologies – benign prostatic hyperplasia and Parkinson's disease – was obtained in clinical studies. In addition, neuroprotective antioxidant, antimutagenic, radioprotective, immunomodulating MPhA action have been confirmed [22, 25-29].

In other words the activities of Schizandrin and Schizantherin A, according to the scientific literature and in silico analysis, correspond to the properties we studied for MPhA which fully fits into the concept of...
a medication for preventive oncology. Of course, antitumor and protective effects are the main properties that medications for preventive oncology should have.

4. Conclusions

For standardization and identification of Multiphytoadaptogen for preventive oncology

the tandem HPLC/MS-MS mass spectrometry method has been successfully applied to determine secondary metabolites from *Schisandra chinensis* – lignans Schizandrine and Schizantherin A as components of the original herbal formula. Lignans Schizandrin and Schizantherin A were identified translocated into Multiphytoadaptogen as well as into *Schisandra chinensis* fruits extract by the technology developed.

Chromatograms and spectra obtained during the research can be used for standardization and identification of Multiphytoadaptogen. The results are also important for justification the biological activity of the Multiphytoadaptogen pharmaceutical composition, taking into account the lignans group components of the *Schisandra chinensis* BAS.

The results of the computational estimation correspond to the data obtained for Mul-tiphytoadaptogen in *vivo*, in *vivo* and in clinical studies. However, in *silico* analysis of predicted *Schisandra chinensis* phytocomponents antitumor properties made it possible to identify some additional probable antineoplastic effects. The variety of the most potential mechanisms for achieving the pharmacological effect positively characterizes the pleiotropy of individual secondary metabolites and their complexes. The information obtained about the most likely additive/synergistic mechanisms of action justifies the use of extracts in one mixture and also reveals the further prospects for investigations.

So, the possibility of complex phytopreparations standardization and identification which include lignans, secondary metabolites from *Schisandra chinensis* is demonstrated. The latter can be included in the regulatory documentation when registering a drug based on MPhA.

The results of the research also suggest that the activity of Schizandrin and Schizantherin A, according to the scientific literature and in *silico* analysis, corresponds to the properties earlier obtained for MPhA, which completely fits into the concept of a drug – homeostasis regulator adaptogen for preventive oncology.

References

13. Kaur, P.; et al. Immunopotentiating significance of conventionally used plant adaptogens as modulators in biochemical and molecular signalling pathways in
28. Alperina, E.L.; Bocharov, E.V.; Bocharova, O.A. Actual problems of neuroimmunopathology; Genius Media: Moscow, Russia, 2012, p 423.
42. Kosman, V.M.; et al. Pharmacokinetics of lignans from Schisandra chinensis. Review on Clinical Pharmacology and Medicinal Therapy 2015, 13, 3-21
43. Poroikov, V.V. Computer-aided drug design: From discovery of novel pharmaceutical agents to systems pharmacology. Biochemistry (Moscow), Supplement Series B: Biomedical Chemistry. 2020, 14, 216-227. DOI: 10.1134/S1990750820030117